Abstract 1524
Background
Treatment of EGFR mutation-positive NSCLC has been revolutionized with the development of EGFR tyrosine kinase inhibitors (TKIs). Three generations of TKIs are now available (1st: erlotinib, gefitinib; 2nd: afatinib, dacomitinib; 3rd: osimertinib). Osimertinib has been developed as second-line treatment after a first-line TKI 1G or 2G when patients progressed with T790M-positive tumors, the most frequent mechanism of resistance. While osimertinib may also be given as first-line treatment, limited data exists on the real life effectiveness of the TKIs sequencing approach: TKI 1G or 2G followed by osimertinib. The French National medico administrative claim database (SNDS) offers the opportunity to estimate the effectiveness parameters for these patients in France.
Methods
Based on SNDS, a historic cohort of patients with a diagnosis of EGFR-mutated NSCLC treated, after a first-line with a TKI 1G or 2G, with osimertinib in second-line between 2015 and 2017 was extracted. Follow-up was conducted until December 31st 2017. Patients’ characteristics, Time on treatments and Overall survival were analysed.
Results
1,404 NSCLC patients have been treated with osimertinib in the database between 2015 and 2017. Among them, 509 had a previous treatment with TKI 1G or 2G without any other anticancer drug before osimertinib initiation, and constitute the analysed population. Mean age was 70.9 (29.1% were above 80 years old), 25.7% were males. Median time on TKI treatment (between the beginning of the first TKI 1G or 2G until discontinuation of osimertinib) was not reached but the percentages of patients still treated were: 83.8% at 24 months and 75.5% at 36 months. Median overall survival was not reached but the percentages of patients still alive were: 79.6% at 24 months and 70.3% at 36 months. Updated data will be presented at the meeting.
Conclusions
Our cohort confirms the prolonged time on TKI treatment and survival rates of patients receiving TKI 1G or 2G followed by osimertinib in a real life setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Boehringer Ingelheim.
Disclosure
N. Girard: Honoraria (self): AstraZeneca; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): GlaxoSmithKline; Honoraria (self): Hoffmann La Roche; Honoraria (self): Lilly; Honoraria (self): Merck Sharp Dohme; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Takeda. S. Bouee: Full / Part-time employment: CEMKA. D. Moro-Sibilot: Honoraria (self), Honoraria (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self), Honoraria (institution): Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Honoraria (institution): Roche; Honoraria (self), Advisory / Consultancy: Takeda; Honoraria (self), Advisory / Consultancy: AbbVie. C. Emery: Full / Part-time employment, CEMKA received a grant from Boehringer Ingelheim to perform the statistical analysis of this study : CEMKA. K. Le Lay: Full / Part-time employment: Boehringer Ingelheim. L. Luciani: Full / Part-time employment: Boehringer Ingelheim. C. Maritaz: Full / Part-time employment: 4. Boehringer Ingelheim. C. Chouaid: Honoraria (self): AstraZeneca; Honoraria (self): Boehringer Ingelheim; Honoraria (self): GlaxoSmithKline; Honoraria (self): Roche; Honoraria (self): Sanofi; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Lilly; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Takeda; Honoraria (self): Bayer; Honoraria (self): Amgen.
Resources from the same session
4085 - A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
Presenter: Anthony Tolcher
Session: Poster Display session 1
Resources:
Abstract
1054 - Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers
Presenter: Philip Clingan
Session: Poster Display session 1
Resources:
Abstract
4264 - A Phase I study of tinostamustine in patients (pts) with advanced solid tumours
Presenter: Alain Mita
Session: Poster Display session 1
Resources:
Abstract
3811 - Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors
Presenter: Santiago Ponce Aix
Session: Poster Display session 1
Resources:
Abstract
1311 - A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors
Presenter: Aaron Tan
Session: Poster Display session 1
Resources:
Abstract
3482 - Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
Presenter: Sanne Huijberts
Session: Poster Display session 1
Resources:
Abstract
4749 - Pharmacokinetic (PK) and updated survival data from the Canadian Cancer Trials Group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
Presenter: Desiree Hao
Session: Poster Display session 1
Resources:
Abstract
4530 - A Phase 2a clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
Presenter: Funda Meric-Bernstam
Session: Poster Display session 1
Resources:
Abstract
4280 - Updated Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Tumors: Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster Display session 1
Resources:
Abstract
6144 - An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors
Presenter: Christopher Jackson
Session: Poster Display session 1
Resources:
Abstract